XXXX -induced sexual dysfunction does not involve increased hepatic metabolism of @entity251 nor increased circulating levels of @entity2819 .

@entity251 @entity323 @entity409 @entity3409 @entity2819 @entity35 @entity99 @entity10278
Sexually experienced male @entity35 were injected IP with 0, 0.3, 1.5, 3.0, or 6.0 mg/kg @entity10278 . The highest dose was fatal within 48 h of injection. A dose-related deficit in erectile function was observed in ex copula tests 48 h after injection. @entity409 was evident in mating tests 72 h after injection. Hepatic mixed function oxidase activity after 0.3 mg/kg injections was not different from controls, but was diminished by 50% in @entity35 treated with 3.0 mg/kg. The higher @entity3409 doses (1.5 and 3.0 mg/kg) were associated with equivalent and marked reductions in circulating @entity251 levels, and lesser decrements in circulating @entity2819 levels. The @entity35 treated with 1.5 or 3.0 mg/kg @entity10278 lost weight (32 +/- 12 and 39 +/- 9 g, respectively). Relative decapsulated adrenal gland weights were markedly increased in @entity35 treated with 3.0 mg/kg. These data indicate that exposure to @entity3409 is associated with alterations in @entity99 , with @entity323 occurring at the lowest dose. The effects on copulatory behavior are especially striking because it requires some weeks for copulatory behavior to wane following castration.
